CGTX - NASDAQ
Cognition Therapeutics, Inc.
$1.42
+14%Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
At a Glance
Live Snapshotcgtx
Stock Based Compensation
Last Annual Value
2.09M
3-Year CAGR
-16%
5-Year CAGR
34%
10-Year CAGR
138%
Cognition Therapeutics, Inc. Competitors Analysis of Stock Based Compensation
| Company | Stock Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Cognition Therapeutics, Inc. NASDAQ:CGTX | 2.09M | -21.7% | -16.6% | N/A | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 10.84M | -31.8% | -11.7% | -4.3% | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 2.65M | -17.0% | -12.9% | 11.7% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 2.61M | 40.7% | -2.0% | 2.7% | |
 Context Therapeutics Inc. NASDAQ:CNTX | 1.33M | 7.3% | 21.1% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 6.42M | 137.6% | 57.9% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 4.81M | -12.9% | N/A | 2.8% | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 3.76M | -30.3% | -32.3% | -9.8% | |
 Instil Bio, Inc. NASDAQ:TIL | 8.69M | -21.8% | -19.8% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 3.83M | -4.3% | 10.6% | N/A | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 6.80M | 42.0% | 59.4% | N/A |
Cognition Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your CGTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.